

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 March 2003 (06.03.2003)

PCT

(10) International Publication Number  
**WO 03/018005 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/4015**, A61P 25/28
- (21) International Application Number: PCT/JP01/07180
- (22) International Filing Date: 22 August 2001 (22.08.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (71) Applicant (for all designated States except US): **DAIICHI PHARMACEUTICAL CO., LTD.** [JP/JP]; 14-10, Nihonbashi 3-chome, Chuo-ku, Tokyo 103-0027 (JP).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **OTOMO, Eiichi** [JP/JP]; 29-1, Sakuragaoka 4-chome, Tama-shi, Tokyo 206-0013 (JP). **TAKASU, Yoshiyuki** [JP/JP]; c/o DAIICHI PHARMACEUTICAL CO., LTD, Tokyo R & D Center, 16-13, Kita-Kasai 1-chome, Edogawa-ku, Tokyo 134-0081 (JP).
- (74) Agents: **OGURI, Shohei** et al.; Eikoh Patent Office, Ark Mori Building, 28th floor, 12-32, Akasaka 1-chome, Minato-ku, Tokyo 107-6028 (JP).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 03/018005 A1**

(54) Title: use of nefiracetam for treating neurodegeneration

(57) Abstract: N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide and salts thereof are used for the preparation of medications, particularly of pharmaceutical compositions containing it as in an active ingredient, for the treatment of neurodegeneration, in particular in post-stroke human patients. The early administration of nefiracetam or its salt in said pharmaceutical compositions after a stroke allows an improvement of the Activities of Daily Living and the recovery, or at least in improvement in the recovery of, post-stroke patients.

## DESCRIPTION

### USE OF NEFIRACETAM FOR TREATING NEURODEGENERATION

5

#### TECHNICAL FIELD

The present invention concerns the use of a cyclic gamma-aminobutyric acid (GABA) derivative, namely N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide or its salt, for the preparation of medicaments for the treatment of neurodegeneration, particularly after a stroke, for improving the Activities of Daily Living (ADL) after a stroke or for recovering, or at least for improving the recovery of, a post-stroke patient.

The present invention also concerns novel antineurodegenerative pharmaceutical compositions comprising, as an active ingredient, N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide.

15

#### BACKGROUND ART


It is known that a way to assess physical impairment in post-stroke patients, besides the neurological motor and sensory examination, is to quantitate deficits in the performance of daily activity (ADL) according to assessment scales, such as the John Hopkins Functioning Inventory (JHFI) or analogous ones, which determine the patients' ability to accomplish normal operations, in particular keeping the sitting or standing position, walking, washing, dressing, undressing, taking the meals, bath and using lavatory. The assessment, the impairment, as well as and the need of recovery of ADL after stroke are illustrated by Robert G. Robinson "The Clinical Neuropsychiatry of Stroke", 1998, Cambridge University Press, pages 143, 222-225 and 292-293).

Depression is the main disorder associated with stroke and there is a correlation between the severity of depression and the severity of impairment in ADL. For the improvement in the impairment of ADL and, as a consequence, for the improvement in the recovery from stroke, patients are mainly treated with antidepressant drugs and, according to the above cited reference, there are no documented pharmacological treatments, apart from said antidepressants treatments, which improve physical or cognitive recovery from completed stroke (Robert G. Robinson, loc. cit., page 293).

Cyclic GABA derivatives, more particularly 2-oxopyrrolidine derivatives, are compounds extensively used in pharmaceutical compositions for the improvement of memory and attention and are known as mnemotonic or nootropic agents. Typical drugs of this class include 2-oxo-1-pyrrolidineacetamide (piracetam), 1-(4-

methoxybenzoyl)-2-pyrrolidinone (aniracetam) and 4-hydroxy-2-oxo-1-pyrrolidineacetamide (oxiracetam).

It is known (BE 883791 - US 4341790) that anilides of 2-oxo-1-pyrrolidineacetamide show central vasoactive and tranquillizing properties as well as the ability of regulating the metabolism and inhibiting thrombocyte agglutination. Thus, said compounds are deemed to be useful for the treatment of cerebro-  
5 ischaemic or atrophic diseases, brain irrigation disorders, brain atrophic crises as well as of brain aging processes. Among these anilides of 2-oxo-1-pyrrolidineacetamide, the 2,6-dimethylanilide, i.e. N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide, known  
10 and hereinafter referred to as nefiracetam, represented by the formula (A)



has been reported to be effective in prolonging the survival time upon a decrease in blood oxygen level and in relieving failure of memory due to cerebropathy.

15 The literature extensively discloses (see for example E. Ohtomo et al., J Clin. Exp. Med., Suppl., 1994, 170/9, 777-816) the usefulness of nefiracetam in improving psychiatric disorders associated with cerebrovascular diseases such as stroke (cerebral infarction or cerebral hemorrhage), this activity being a consequence of the favorable action of nefiracetam on the cerebral irrigation, as suggested by BE 883791.

20 It is also known (K. Hirata et al., Brain Topography 1996, 8/3, 279-284) that nefiracetam acts as a cerebral metabolic enhancer in improving the mental function impairment in stroke patients, thus confirming the suggestion of BE 833791 which disclosed the metabolism-regulating properties of the compound. Hirata et al., however, conclude that the improvement of mental function tests was not significant.

25 Moreover, it is known (US 5886023) that nefiracetam improves symptoms of cerebrovascular or Alzheimer's type dementia due to a decline in mental function.

All these documents indicate that the efficacy of nefiracetam in the symptomatic treatment of impaired mental function is due to its ability in improving the cerebral irrigation or to its metabolism-regulating properties. Psychiatric symptoms and  
30 cognitive impairment are frequently observed following stroke and negatively affect both the patient and the caregiver.

In the above-cited article of Ohtomo et al., the global results of a clinical study, conducted in two groups of patients to which nefiracetam and, respectively, placebo were administered after a stroke (cerebral infarction or cerebral hemorrhage), showed that the compound improves the psychiatric symptoms but concluded that there was no significant difference between the two groups as far as the activities of daily living were concerned. Thus, according to these results nefiracetam appeared as inactive in improving the disturbances of the activities of daily living in post-stroke patients. A positive effect in this indication could suggest a curative use of a drug for the recovery from a stroke or, at least, for an improved recovery from stroke.

#### DISCLOSURE OF INVENTION

It has now surprisingly been found that, if nefiracetam is administered to a patient, suffering from the consequences of a stroke, early after the event for example within the first 12 months after the stroke, or at the most within the first six months after the stroke, a significant improvement with regard to the global disturbances of the activities of the daily living is observed.

More particularly, it has been found that nefiracetam is able to induce an improvement in the recovery of post-stroke patients, provided that said nefiracetam is administered early after the event for example within the first 12 months after the stroke, at the most within the first six months after said event.

Moreover, it has surprisingly been found that nefiracetam possesses a remarkable neurotrophic activity which allows the regeneration of damaged neurons, thus being able to combat neurodegeneration, and that nefiracetam is particularly effective when the neurodegeneration is due to a stroke (cerebral infarction or cerebral hemorrhage).

Thus, it is an object of the present invention to provide the use of nefiracetam or its salt for the preparation of a medicaments for the treatment of neurodegeneration.

The mechanism by which nefiracetam acts on the neurodegeneration, thus allowing, for example, a recovery or at least an improvement in the recovery from stroke, is unknown because nefiracetam does not possess known biochemical activities which are predictive and known for this action such as, for example an agonism for the 5HT1-A receptor or a positive modulation of AMPA-sensitive glutamate receptors (AMPA indicates  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid).

The neurotrophic, in particular antineurodegenerative, property of nefiracetam was inferred on the basis of the clinical evidence of a significant improvement in the

Activities of the Daily Living and other psychiatric symptoms by early treatment and confirmed by biochemical and animal tests.

Thus, it is another object of the present invention to provide the use of nefiracetam or its salt for the preparation of medicaments for improving the Activities of Daily Living (ADL) in a post-stroke patient. The treatment comprises administering  
5 to a patient an effective dose of nefiracetam, said administration being initiated within the first 12 months after the stroke.

In order to display the best activity, nefiracetam or its salt will be administered early or at least as soon as possible, for example within 12 months, preferably within six  
10 months, advantageously within three months, more preferably within one month after a stroke.

Examples of nefiracetam's salts can include acid addition salts with inorganic or organic acids such as citric acid, tartaric acid, hydrochloric acid, sulfonic acid and the like.

15 Nefiracetam or its salt can be administered in various manner to achieve the desired effect, for example for improving ADL in a post stroke patient or for the recovery of, or at least for improving the recovery of, a post-stroke patient. The compound can be administered alone or in the form of pharmaceutical compositions comprising a pharmacologically effective amount of nefiracetam as an active ingredient  
20 and a pharmaceutical acceptable carrier to the patient to be treated, preferably orally. The oral amount of nefiracetam administered will vary and can be any effective amount according to the physician's prescription. Normally, depending upon the patient and the mode of administration, the quantity of compound administered orally may vary over a wide range to provide from about 1 mg/kg to about 20 mg/kg, usually 1.5 mg/kg to 15  
25 mg/kg of body weight of the patient per dose. Unit doses of nefiracetam in the oral pharmaceutical compositions may contain, for example, from about 50 mg to about 1200 mg, usually from 100 to 600 mg of the compound and may be administered 1 to 4 times daily.

The activity of nefiracetam to improve ADL in post-stroke patients has been  
30 discovered during a controlled clinical trial against placebo. The compound has been administered orally (450 mg/day, three times daily) to 32 post-stroke patients within six months after the event whilst, concurrently, 27 patients received placebo. The two groups of patients were followed during at least 8 weeks and followed up at the end of week 4 and at the end of week 8 on a symptom scale measuring Activities of Daily  
35 Living. The nefiracetam-treated patients showed a moderate or remarkable

improvement, whereas no patient in the group treated with placebo showed an improvement. Among the above 59 patients, 19 received nefiracetam and 10 received placebo within three months after stroke. 41.7% of the nefiracetam-treated patients showed a moderate or remarkable improvement whilst no improvement has been noted in the patients who received placebo. The difference was significant ( $p = 0.035$ ,  $\chi^2$  test). Thus, unlike what the literature seemed to suggest, it has been discovered that nefiracetam has the surprising and unique property of showing a dramatically good activity when given early after stroke.

Further, the action of nefiracetam on the patient who had been treated with nefiracetam early after stroke or later was evaluated. The results are shown in Tables below.

1. Global Improvement Rating

Duration from Stroke	Improvement Rate*	
< 3 months	13/19	68.4%
< 6 months	16/32	50.0%
$\geq$ 6 months	26/98	26.5%
$\geq$ 12 months	18/82	22.0%

Overall	32.3%
---------	-------

\*: Percent Patients Remarkably or Moderately Improved

Duration from Stroke	Improvement Rate		$\chi^2$ Test
< 6 months	16/32	50.0%	P=0.014
$\geq$ 6 months	26/98	26.5%	
< 12 months	24/48	50.0%	P<0.001
$\geq$ 12 months	18/82	22.0%	

2. Psychiatric Symptoms

Duration from Stroke	Improvement Rate*	
< 3 months	13/19	68.4%
< 6 months	16/32	50.0%
$\geq$ 6 months	24/98	24.5%
$\geq$ 12 months	16/82	19.5%

Overall	30.8%
---------	-------

\*: Percent Patients Remarkably or Moderately Improved

Duration from Stroke	Improvement Rate		$\chi^2$ Test
< 6 months	16/32	50.0%	P=0.007
$\geq$ 6 months	24/98	24.5%	
< 12 months	24/48	50.0%	P<0.001
$\geq$ 12 months	16/82	19.5%	

3. Reduced Spontaneity

5

Duration from Stroke	Improvement Rate*	
< 3 months	11/18	61.1%
< 6 months	14/30	46.7%
$\geq$ 6 months	15/94	16.0%
$\geq$ 12 months	8/79	10.1%

Overall	23.4%
---------	-------

\*: Percent Patients Remarkably or Moderately Improved

Duration from Stroke	Improvement Rate		$\chi^2$ Test
< 6 months	14/30	46.7%	P<0.001
$\geq$ 6 months	15/94	16.0%	
< 12 months	21/45	46.7%	P<0.001
$\geq$ 12 months	8/79	10.1%	

4. Emotional Disturbance

10

Duration from Stroke	Improvement Rate*	
< 3 months	12/17	70.6%
< 6 months	14/29	48.3%
$\geq$ 6 months	14/95	14.7%
$\geq$ 12 months	7/81	8.6%

Overall	22.6%
---------	-------

\*: Percent Patients Remarkably or Moderately Improved

Duration from Stroke	Improvement Rate		$\chi^2$ Test
< 6 months	14/29	48.3%	P<0.001
$\geq$ 6 months	14/95	14.7%	
< 12 months	21/43	48.8%	P<0.001
$\geq$ 12 months	7/81	8.6%	

5. Intellectual Dysfunction

Duration from Stroke	Improvement Rate*	
< 3 months	7/16	43.8%
< 6 months	8/27	29.6%
$\geq$ 6 months	5/82	6.1%
$\geq$ 12 months	4/70	5.7%

Overall	11.9%
---------	-------

5                    \*: Percent Patients Remarkably or Moderately Improved

Duration from Stroke	Improvement Rate		$\chi^2$ Test
< 6 months	8/27	29.6%	P=0.001
$\geq$ 6 months	5/82	6.1%	
< 12 months	9/39	23.1%	P=0.007
$\geq$ 12 months	4/70	5.7%	

6. ADL Improvement

Duration from Stroke	Improvement Rate*		$\chi^2$ Test
< 3 months	5/12	41.7%	P<0.001
$\geq$ 3 months	1/81	1.2%	
< 6months	5/23	21.7%	P<0.001
$\geq$ 6 months	1/70	1.4%	
< 12 months	5/35	14.3%	P=0.017
$\geq$ 12 months	1/58	1.7%	

10                    \*: Percent Patients Remarkably or Moderately Improved



According to the results of this study, the early treatment with nefiracetam after stroke objectively improves the recovery from stroke, as shown by the fact that, besides psychiatric symptoms such as emotional disturbance and reduced spontaneity, also intellectual dysfunction dramatically improved in a high percent of nefiracetam-treated patients whilst no improvement was noted in the placebo-treated patients. Moreover, nefiracetam surprisingly tends to improve neurological signs and incontinence of urines. Thus nefiracetam, when administered early after the event, appears to be the first drug which is able to induce a recovery from stroke or, at least, to improve the recovery from stroke.

10           The mechanism of action of nefiracetam and its salt for this indication, which is not bound to the nootropic activity of the drug, is unknown, but it is believed that its surprising effect in improving ADL of a patient after a stroke or in the recovery of, or at least in improving the recovery of, a post-stroke patient, is due to an action against the neurodegeneration and a true brain repair.

15           Biological in vitro studies carried out on primary cultures of hippocampal and cortical rat embryo neurons showed that nefiracetam, at concentrations of 0.1, 1, 10 and 100 micromoles/l, displays a neurotrophic effect on said neurons by significantly increasing neurite outgrowth. This effect is similar to that induced by basic Fibroblast Growth Factor (bFGF), for which a function as a neurotrophic factor in the brain has been suggested (R.S. Morrison et al., Proceedings of the National Academy of Sciences, 20 1986, 83, 7537-7541; K. Abe et al., 1990, 53, 221-227) and such an effect is surprisingly potentiated by bFGF in hippocampal neurons. This finding strongly suggests that nefiracetam, which is well absorbed and crosses the hematoencephalic barrier, should allow the regeneration of damaged brain neurons in mammals, for example after a stroke, thus favorising brain repair and can be used for combating neurodegeneration in mammals, particularly after a stroke.

25           This assumption is confirmed by the effect of nefiracetam on spatial learning and retention in rats with cerebral embolism, treated for 9 days with nefiracetam or vehicle, starting within 24 hours of embolization. More particularly, a clear difference between nefiracetam and vehicle-treated animals was observed in the place-learning watermaze task 7 to 9 days after embolization. Moreover, the effect of nefiracetam is maintained even after washout (at day 17 after embolization). This result is predictive of a brain repair effect and shows that the administration of nefiracetam after a stroke provoked by an embolism induces a recovery of the cognition after the stroke.

Thus, it is a third object of the present invention to provide the use of nefiracetam or its salt for the preparation of medicaments for the recovery, or at least for improving the recovery of, a post-stroke patient. The treatment consists of administering to a patient an effective amount of nefiracetam, said administration being initiated  
5 within 12 months, preferably within six months, advantageously within three months, more preferably within one month, from the stroke. More particularly, the medicament consists of a pharmaceutical composition containing a pharmacologically effective amount of nefiracetam or its salt, as an active ingredient, and a pharmaceutically acceptable carrier. Said effective amount of nefiracetam is advantageously from 50 to  
10 1200 mg, preferably from 100 to 600 mg per unit dose.

It is a fourth object of the present invention to provide a pharmaceutical composition for treating neurodegeneration comprising a pharmacologically effective amount of nefiracetam or its salt, as an active ingredient, and a pharmaceutically acceptable carrier.

15 It is a fifth object of the present invention to provide a pharmaceutical composition for the improvement of ADL in post-stroke patients, comprising a pharmacologically effective amount of nefiracetam or its salt, as an active ingredient, and a pharmaceutically acceptable carrier.

It is a sixth object of the present invention to provide a pharmaceutical  
20 composition for the recovery of, or at least for improving the recovery of, a post-stroke patient, comprising a pharmacologically effective amount of nefiracetam or its salt, as an active ingredient, and a pharmaceutically acceptable carrier.

As set forth above, said compositions are preferably in orally administrable dosage unit form, said dosage unit forms advantageously containing 50-1200 mg,  
25 preferably 100-600 mg, of nefiracetam or its salt per unit dose.

It is a seventh object of the present invention to provide a method for treating neurodegeneration in a mammal which comprises administering to said mammal in need of said treatment an effective amount of nefiracetam or its salt, more particularly a pharmaceutical composition comprising a pharmacological effective amount of  
30 nefiracetam or its salt, as an active ingredient, and a pharmaceutically acceptable carrier. According to a preferred method, nefiracetam or its salt is administered to treat neurodegeneration as a consequence of a stroke. Preferred mammals to be treated are post-stroke human patients, advantageously post-stroke patients having impaired ADL.

It is an eighth object of the present invention to provide a method for improving  
35 ADL in a post-stroke patient which comprises administering to said patient an effective

amount of nefiracetam or its salt, said administration being initiated within 12 months, preferably within six months, advantageously within three months, more preferably within one month after stroke.

It is a ninth object of the present invention to provide a method for recovering, or at least for improving the recovery of, a post-stroke patient which comprises administering to said patient an effective amount of nefiracetam or its salt, said administration being initiated within 12 months, preferably within six months, advantageously within three months, more preferably within one month after stroke.

These methods are carried out by administering nefiracetam or its salt in pharmaceutical compositions as illustrated above.

It is a tenth object of the present invention to provide the use of nefiracetam or its salt for the preparation of a medicament for the early treatment of stroke

The oral pharmaceutical compositions in which form nefiracetam or its salt will normally be utilized, are prepared in a manner well known per se in the pharmaceutical art and usually comprise nefiracetam, as an active ingredient, in admixture or otherwise in association with a pharmaceutically acceptable additives. For making those formulations said active ingredient will usually be mixed with, such as, excipients, disintegrator or disintegrating aids, binders, lubricants, coating agents, coloring agents and diluents.

As pharmaceutically acceptable additives for the manufacture of pharmaceutical compositions, for example, excipients such as glucose, lactose, D-mannitol, starch, and crystalline cellulose; disintegrators or disintegrating aids such as carboxymethylcellulose, starch, and carboxymethylcellulose calcium; binders such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, and gelatine; lubricants such as magnesium stearate and talc; and coating agents such as hydroxypropylmethylcellulose, saccharose, polyethylene glycol, and titanium oxide may be used.

The compositions may be administered to the post-stroke patient for example in the form of tablets, capsules, powders, subtilized granules, granules, dragees, solution, syrups or suspensions.

The example of the pharmaceutical composition;

Tablets

	Nefiracetam	100 mg
35	Lactose	60 mg

Cornstarch	30 mg
Hydroxypropylcellulose	4.5 mg
Low substituted hydroxypropylcellulose	5 mg
Magnesium stearate	0.5 mg

5

---

 200 mg

### BEST MODE FOR CARRYING OUT INVENTION

The following Example illustrate the invention without, however, limiting it.

#### 10 **EXAMPLE 1**

##### *Effect of Nefiracetam on Spatial Learning of Rats with Cerebral Embolism*

In male Wistar rats weighing 190-220 g a total of 700 microspheres (48  $\mu$ m in diameter) were injected into the right common carotid artery of each animal, whereby a quasi-immediate embolism occurs. The embolized animals were randomly divided into 15 2 groups, each of 13 animals with same neurological deficit, designated as "Control" (embolism plus Vehicle), or "Nefiracetam" (embolism plus nefiracetam 10 mg/kg/day). In addition, a group of 13 "Normal (Sham)" non-embolized animals were used. The administration of nefiracetam or of its vehicle started within the same day of embolization and treatment lasted 9 days. Seven days after embolization, the embolized 20 rats were submitted to a watermaze test, said watermaze being adapted from the Morris water task. The time taken to find the platform (latency) was determined. If a rat failed to find the platform within 180 seconds, the trial was terminated and the rat was assigned a score of 180 seconds. The experiment was carried out in two different sessions. In the first session, at the seventh day embolized rats were submitted to the 25 spatial learning test performed three trials per day for three days (from day 7 to day 9). In the second session, one week after the last day of spatial learning test (i.e. on day 17), a retention test was performed whereby each rat was given three consecutive trials to learn and remember the location of the platform. Table 1 shows the average latency (in seconds) to reach the platform in both spatial learning and retention tests. This table 30 shows the clear difference in learning ability between nefiracetam- and vehicle-treated (control) brain-injured animals when tested at days 7-9 post-embolism. This difference is statistically significant ( $p < 0.05$  compared to control, t-test). This table also shows a clear effect of nefiracetam in the retention test, wherein a remarkable difference between the nefiracetam- and vehicle-treated, embolized animals is observed.

35

Table 1

Latency (Sec.)

Group	n	Spatial learning test			Retention test
		Day 7	Day 8	Day 9	Day 17
Normal (Sham)	13	130.9 ± 16.8	61.2 ± 15.0	22.5 ± 5.9	31.7 ± 13.1
Control	13	159.7 ± 11.4	146.0 ± 13.0	127.5 ± 17.0	133.4 ± 15.0
Nefiracetam	13	147.6 ± 14.1	83.7 ± 17.4	93.1 ± 16.2	72.2 ± 17.0

5 Table 2 summarizes the number of animals which, under the above-described conditions, failed to find the platform within 180 seconds.

Table 2

Number of rats which failed to find the platform within 180 Sec.

Group	n	Spatial learning test			Retention test
		Day 7	Day 8	Day 9	Day 17
Normal (Sham)	13	5	1	0	1
Control	13	10	7	5	7
Nefiracetam	13	8	2	2	2

10 Table 2 shows the clear difference between the nefiracetam-treated animals and the controls.

### INDUSTRIAL APPLICABILITY

15 N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide or its salt is used for the preparation of medicaments, particularly of pharmaceutical compositions containing it as an active ingredient, for the treatment of neurodegeneration, in particular in post-stroke human patients. The early administration of nefiracetam in the pharmaceutical compositions after a stroke allows an improvement of the Activities of Daily Living and the recovery, or at least in improvement in the recovery of, post-stroke patients

20

**CLAIMS**

1. Use of nefiracetam or its salt for the preparation of a medicament for the treatment of neurodegeneration.
2. The use of claim 1, in which said neurodegeneration is a post-stroke neurodegeneration.
3. The use of claim 2, in which said treatment is an early treatment of post-stroke neurodegeneration.
4. The use of claims 2 or 3, for the preparation of a medicament for improving ADL in a post-stroke patient.
5. The use of claim 2 or 3, for the preparation of a medicament for the recovery, or at least for improving the recovery, of a post-stroke patient.
6. A pharmaceutical composition for the treatment of neurodegeneration comprising a pharmacologically effective amount of nefiracetam or its salt, as an active ingredient, and a pharmaceutical acceptable carrier.
7. The composition of claim 6, for the treatment of post-stroke neurodegeneration.
8. The composition of claim 6 for the treatment of impaired ADL in post stroke patients.
9. The composition of claim 6 for the recovery, or at least for improving the recovery of, post-stroke patients.
10. The composition of claims 6-9 which is in an orally administrable unit dose.
11. The composition of claim 10 in which said unit dose contains from 50 to 1200 mg of nefiracetam.
12. The composition of claim 11, in which said unit dose contains from 100 to 600 mg of nefiracetam.
13. A method for treating neurodegeneration in a mammal which comprises administering to said mammal in need of said treatment an effective dose of nefiracetam or its salt.
14. The method of claim 13 in which said neurodegeneration is a consequence of a stroke.
15. The method of claim 14 in which said mammal is a post-stroke human patient.
16. The method of claim 15 in which said mammal is a post-stroke patient having an impaired ADL
17. A method for improving Activities of Daily Living (ADL) in a post-stroke patient which comprises administering to said patient an effective amount of nefiracetam or its salt, said administration being initiated within 12 months after said stroke.

18. A method for recovering, or at least for improving the recovery of, a post-stroke patient which comprises administering to said patient an effective amount of nefiracetam or its salt, said administration being initiated within 12 months after said stroke.
- 5 19. The method of claim 17 or 18 in which said treatment is initiated within six months after said stroke.
20. The method of claim 17 or 18 in which said treatment is initiated within three months after said stroke.
21. The method of claim 17 or 18 in which said treatment is initiated within one month  
10 after said stroke.
22. The method of claim 13-21 in which said effective dose is administered in form of a pharmaceutical composition comprising a pharmacologically effective amount of nefiracetam or its salt, as an active ingredient, and a pharmaceutical acceptable carrier.
- 15 23. The method of claim 22 in which said composition is in oral unit dose form.
24. The method of claim 22 in which said effective amount is from 50 to 1200 mg of nefiracetam per unit dose.
25. The method of claim 24 in which said effective amount is from 100 to 600 mg of nefiracetam per unit dose.

INTERNATIONAL SEARCH REPORT  
 WO 03/018005

International Application No  
 PCT/JP 01/PCT/JP01/07180

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 A61K31/4015 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 886 023 A (E. OTOMO ET AL) 23 March 1999 (1999-03-23) cited in the application claims 1-24	6-12
X	EP 1 020 189 A (DAIICHI PHARMACEUTICAL CO. LTD.) 19 July 2000 (2000-07-19) claims 1-9 page 4, line 28 - line 32	6-12
X	EP 1 022 029 A (DAIICHI PHARMACEUTICAL CO. LTD.) 26 July 2000 (2000-07-26) claims 1-6,10,13-17	6-12
	-/--	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

22 April 2002

Date of mailing of the international search report

03/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Siatou, E



## INTERNATIONAL SEARCH REPORT

WO 03/018005

International Application No

PCT/JP 01/PCT/JP01/07180

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE EMBASE 'Online! ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; ENDERBY P. ET AL: "Effect of piracetam on recovery and rehabilitation after stroke: A double- blind, placebo-controlled study." retrieved from STN Database accession no. 94237142 XP002170792 abstract &amp; CLINICAL NEUROPHARMACOLOGY, (1994) 17/4 (320-331).,</p> <p style="text-align: center;">-----</p>	1-25

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 01/07180

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5886023	A	23-03-1999	AT 203402 T	15-08-2001
			AU 1595492 A	05-11-1992
			AU 697936 B2	22-10-1998
			AU 3774595 A	07-03-1996
			CA 2067614 A1	03-11-1992
			CS 9201306 A3	18-11-1992
			DE 69231955 D1	30-08-2001
			DE 69231955 T2	04-04-2002
			DK 515866 T3	24-09-2001
			EP 0515866 A1	02-12-1992
			ES 2160097 T3	01-11-2001
			HU 62790 A2	28-06-1993
			IE 921377 A1	04-11-1992
			IL 101738 A	26-01-1999
			JP 5163145 A	29-06-1993
			MX 9202058 A1	01-03-1993
			NO 921724 A	03-11-1992
			PT 515866 T	30-11-2001
			SG 49650 A1	15-06-1998
			SK 279285 B6	09-09-1998
			RU 2070042 C1	10-12-1996
			JP 5163144 A	29-06-1993
			ZA 9203134 A	27-01-1993
			EP 1020189	A
EP 1020189 A1	19-07-2000			
US 6281242 B1	28-08-2001			
CN 1264301 T	23-08-2000			
WO 9903466 A1	28-01-1999			
EP 1022029	A	26-07-2000	JP 11080027 A	23-03-1999
			AU 9003598 A	05-04-1999
			BR 9815370 A	24-10-2000
			CA 2301782 A1	25-03-1999
			EP 1022029 A1	26-07-2000
			NO 20001196 A	10-05-2000
			CN 1270528 T	18-10-2000
			WO 9913911 A1	25-03-1999